RUNX1 and acute myeloid leukemia: Conversely, Chou et al. [17] observed a favorable prognostic impact of RUNX1 mutations in AML patients undergoing allo-HSCT, while Gaidzik et al. [13] found improved relapse-free survival (RFS) in RUNX1+ AML patients post-transplantation.